eLearning: Measuring treatment success and failure

Uwe Reuter discusses how to assess the efficacy of migraine treatment and when to change treatment plans.

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME. NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NACCME designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity was launched on July 20, 2021. The data were correct at time of publication and no further updates have been made to the content

Learning objectives

After taking part in this case study, you will be able to:

  • Describe the efficacy endpoints for acute migraine treatments and how these should inform treatment decisions in clinical practice.
  • Utilize patient-reported outcome tools to assess treatment efficacy.

Uwe Reuter

View Biography

Login or create a free account to access this activity

Create a Free Account

Already Registered? Login Here

Forgot Password?
Scroll to Top

Uwe Reuter, Program Director

Professor of Neurology, Charité University Hospital, Berlin, Germany

Prof Dr Uwe Reuter is a neurologist and partner in the headache program at Charité Universitätsmedizin Berlin, Germany. Upon completing his residency training in Berlin he attended Harvard Medical School as a postdoctoral fellow. During his time in Boston he focused on basic research in primary headaches and migraine aura, and published several peer-reviewed publications in high impact journals. Uwe Reuter has been the principal investigator in numerous clinical trials and projects. He has published multiple manuscripts on CGRP and is the lead author in the first placebo controlled clinical trial with a monoclonal CGRP antibody for migraine prevention in patients, who previously did not respond to 2-4 conventional oral migraine preventatives.

He is a member of several national and international headache organizations and currently serves as a board member of the European Headache Federation.

Disclosures

Uwe Reuter discloses financial support and/or sponsorship from Allergan, Amgen, Novartis, Eli Lilly, TEVA, Medscape, and StreamedUp.

Close

Sign up for eAlerts or take our quiz first and sign up at the end.

Just Sign Me Up
Take the Quiz

eAlerts